Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Adimab LLC, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Adimab Raises US$13.8 Million In Series F Financing 13
Partnerships 15
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16
iTeos Therapeutics Enters into Agreement with Adimab 17
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18
Adimab Enters into Research Agreement with Kite Pharma 19
Adimab Enters into Discovery Agreement with Celgene 20
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21
Adimab Enters into Agreement with Acceleron Pharma 22
Adimab Enters into Agreement with Oncothyreon 23
Adimab Enters into Agreement with Surface Oncology 24
Adimab Enters into Agreement with Potenza Therapeutics 25
Five Prime Therapeutics Enters Into Research Agreement With Adimab 26
Jounce Therapeutics Enters Into Research Agreement With Adimab 27
Alector Enters Into Research Agreement With Adimab 28
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29
Adimab Expands Agreement with Innovent Biologics 30
GlaxoSmithKline Expands its Partnership with Adimab 31
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33
Adimab Enters Into Co-Development Agreement With Gilead Sciences 34
Adimab Enters Into Co-Development Agreement With Biogen Idec 35
Adimab Enters Into Co-Development Agreement With Novo Nordisk 36
Arsanis Enters into Agreement with Adimab 37
Licensing Agreements 38
Eli Lilly Enters into Licensing Agreement with Adimab 38
Arsanis Enters into Licensing Agreement with Adimab 39
Kite Pharma Exercises Option for Licensing Agreement with Adimab 40
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 41
Adimab Enters into Licensing Agreement with Merck 42
Mersana Therapeutics Amends its Licensing Agreement with Adimab 43
Adimab Enters Into Licensing Agreement With Novo Nordisk 44
Biogen Idec Enters Into Licensing Agreement With Adimab 45
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 47
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 48
Adimab LLC – Key Competitors 49
Adimab LLC – Key Employees 50
Adimab LLC – Locations And Subsidiaries 51
Head Office 51
Recent Developments 52
Product News 52
04/25/2016: Adimab Expands Bispecific Antibody Offering with Novel CD3 Program 52
Feb 18, 2016: Adimab Scientists Report the Isolation of Highly Potent Anti-Ebola Virus Antibodies from Recent Zaire Outbreak 53
Other Significant Developments 54
Jan 10, 2017: Adimab Provides Annual Update on 2016 Partnerships and Milestones 54
Apr 25, 2016: Adimab Expands Bispecific Antibody Offering with Novel CD3 Program 55
Jan 11, 2016: Adimab Provides Update on Recent Partnerships and Milestones 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
Adimab LLC, Pharmaceuticals & Healthcare, Key Facts 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Adimab LLC, Deals By Therapy Area, 2011 to YTD 2017 10
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Adimab Raises US$13.8 Million In Series F Financing 13
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16
iTeos Therapeutics Enters into Agreement with Adimab 17
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18
Adimab Enters into Research Agreement with Kite Pharma 19
Adimab Enters into Discovery Agreement with Celgene 20
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21
Adimab Enters into Agreement with Acceleron Pharma 22
Adimab Enters into Agreement with Oncothyreon 23
Adimab Enters into Agreement with Surface Oncology 24
Adimab Enters into Agreement with Potenza Therapeutics 25
Five Prime Therapeutics Enters Into Research Agreement With Adimab 26
Jounce Therapeutics Enters Into Research Agreement With Adimab 27
Alector Enters Into Research Agreement With Adimab 28
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29
Adimab Expands Agreement with Innovent Biologics 30
GlaxoSmithKline Expands its Partnership with Adimab 31
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33
Adimab Enters Into Co-Development Agreement With Gilead Sciences 34
Adimab Enters Into Co-Development Agreement With Biogen Idec 35
Adimab Enters Into Co-Development Agreement With Novo Nordisk 36
Arsanis Enters into Agreement with Adimab 37
Eli Lilly Enters into Licensing Agreement with Adimab 38
Arsanis Enters into Licensing Agreement with Adimab 39
Kite Pharma Exercises Option for Licensing Agreement with Adimab 40
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 41
Adimab Enters into Licensing Agreement with Merck 42
Mersana Therapeutics Amends its Licensing Agreement with Adimab 43
Adimab Enters Into Licensing Agreement With Novo Nordisk 44
Biogen Idec Enters Into Licensing Agreement With Adimab 45
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 47
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 48
Adimab LLC, Key Competitors 49
Adimab LLC, Key Employees 50